Glory October 17th, Heisen Pharmaceuticals (001367.SZ) released its third quarter report in 2024. In the third quarter of 2024, the company achieved a revenue of 0.109 billion yuan, a 21.83% increase from the same period last year; net profit attributable to shareholders of the listed company was 28.9097 million yuan, a 10.68% increase from the same period last year; net profit after deducting non-recurring gains and losses was 29.5743 million yuan, a 15.82% increase from the same period last year; basic earnings per share was 0.28 yuan per share.
海森药业(001367.SZ)：第三季度净利润2890.97万元 同比增长10.68%
Haisen Pharmaceutical (001367.SZ): The net income in the third quarter was 28.9097 million yuan, a year-on-year increase of 10.68%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated